Progyny sees FY24 EPS 1.54-$1.59, consensus $1.00

Sees FY24 revenue $1.3B-$1.32B, consensus $1.32B…Substantially all of the clients added in the most recent selling season have already launched their benefit, with a handful expected to do so over the coming months. Once all new clients are live in 2024, the Company anticipates having more than 460 clients, representing an estimated 6.7 million covered lives. “We believe the macro trends that have been fueling our growth remain intact, as reflected in our strong performance in 2023. Accordingly, we’re pleased to announce our guidance for the first quarter and full year 2024, which reflects both significant ongoing topline growth, as well as the continued expansion of our margins,” continued Anevski. “The first quarter range reflects a short-term shift in treatment mix as compared to customary levels, resulting in an approximately $15 million headwind to revenue. We’ve seen treatment mix return to more customary levels at this time, which is reflected in the full year guidance ranges.” Revenue is projected to be $1,285 million to $1,315 million, reflecting growth of 18% to 21%